X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/21/2850615/0/en/Bolt-Biotherapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/02/27/2835836/0/en/Bolt-Biotherapeutics-to-Present-at-the-TD-Cowen-44th-Annual-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2023/12/05/2790780/0/en/Bolt-Biotherapeutics-Enrolls-First-Patient-in-Phase-2-Clinical-Study-Evaluating-BDC-1001-in-Patients-with-HER2-Positive-Breast-Cancer-Previously-Treated-with-Enhertu.html
https://www.globenewswire.com//news-release/2023/11/09/2777794/0/en/Bolt-Biotherapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2023/11/07/2774908/0/en/Bolt-Biotherapeutics-to-Present-at-Stifel-2023-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/10/23/2764894/0/en/Bolt-Biotherapeutics-Presents-Updated-Clinical-Data-from-Phase-1-Dose-Escalation-Trial-of-BDC-1001-as-Monotherapy-and-in-Combination-with-Nivolumab-in-HER2-Expressing-Tumors-at-ESM.html
https://www.globenewswire.com//news-release/2023/10/18/2762201/0/en/Bolt-Biotherapeutics-to-Present-Data-at-the-Society-for-Immunotherapy-of-Cancer-s-2023-Annual-Meeting.html
https://www.globenewswire.com//news-release/2023/10/17/2761337/0/en/Bolt-Biotherapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Study-of-BDC-3042-in-Patients-with-Advanced-Cancers.html
https://www.globenewswire.com//news-release/2023/10/16/2760481/0/en/Bolt-Biotherapeutics-to-Present-New-Clinical-Data-from-Completed-Phase-1-2-Dose-Escalation-Trial-of-BDC-1001-in-HER2-Expressing-Solid-Tumors-at-the-ESMO-Congress-2023.html
https://www.globenewswire.com//news-release/2023/09/28/2751060/0/en/Bolt-Biotherapeutics-Receives-Orphan-Drug-Designation-for-BDC-1001-for-Treatment-of-Gastric-Cancers.html
Market Place
Share 
